Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markolf Hanefeld

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
International Journal of Obesity (2005)|May 26, 2018
The anorexigenic peptide neurotensin relates to insulin sensitivity in obese patients after BPD or RYGB metabolic surgeryChristian von Loeffelholz, Lidia Castagneto Gissey, Tina Schumann, et al.
Diabetes Care|May 13, 2011
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) studyMichael R MacDonald, Mark C Petrie, Philip D Home, et al.
Diabetes Care|April 9, 2013
Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE)Eva M Lonn, Jackie Bosch, Rafael Diaz, et al.
The Lancet. Diabetes & Endocrinology|June 21, 2021
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trialHarpreet S Bajaj, Hertzel C Gerstein, Purnima Rao-Melacini, et al.
Plos One|October 27, 2010
Differential white blood cell count and type 2 diabetes: systematic review and meta-analysis of cross-sectional and prospective studiesEffrossyni Gkrania-Klotsas, Zheng Ye, Andrew J Cooper, et al.
The Lancet. Diabetes & Endocrinology|January 12, 2020
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trialHertzel C Gerstein, Robert Hart, Helen M Colhoun, et al.
Diabetes, Obesity & Metabolism|June 3, 2017
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutideHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Molecular Genetics and Metabolism|July 14, 2006
Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analysesTakafumi Tsuchiya, Peter E H Schwarz, Laura Del Bosque-Plata, et al.
Lancet (London, England)|June 14, 2019
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Lancet (London, England)|June 14, 2019
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
International Journal of Obesity (2005)|May 26, 2018
The anorexigenic peptide neurotensin relates to insulin sensitivity in obese patients after BPD or RYGB metabolic surgeryChristian von Loeffelholz, Lidia Castagneto Gissey, Tina Schumann, et al.
Diabetes Care|May 13, 2011
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) studyMichael R MacDonald, Mark C Petrie, Philip D Home, et al.
Diabetes Care|April 9, 2013
Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE)Eva M Lonn, Jackie Bosch, Rafael Diaz, et al.
The Lancet. Diabetes & Endocrinology|June 21, 2021
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trialHarpreet S Bajaj, Hertzel C Gerstein, Purnima Rao-Melacini, et al.
Plos One|October 27, 2010
Differential white blood cell count and type 2 diabetes: systematic review and meta-analysis of cross-sectional and prospective studiesEffrossyni Gkrania-Klotsas, Zheng Ye, Andrew J Cooper, et al.
The Lancet. Diabetes & Endocrinology|January 12, 2020
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trialHertzel C Gerstein, Robert Hart, Helen M Colhoun, et al.
Diabetes, Obesity & Metabolism|June 3, 2017
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutideHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Molecular Genetics and Metabolism|July 14, 2006
Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analysesTakafumi Tsuchiya, Peter E H Schwarz, Laura Del Bosque-Plata, et al.
Lancet (London, England)|June 14, 2019
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Lancet (London, England)|June 14, 2019
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Pageof 13